UroGen Pharma Ltd

Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.

Five biotech stocks highlighted in RTTNews reports have delivered gains ranging from 100% to over 300% since their respective publication dates. Climb Bio Inc. rose 310% to $12.90 from a published price of $3.14 on December 15, 2025, driven by pipeline progress and positive early clinical data for Budoprutug and CLYM116. Tectonic Therapeutic Inc. gained 121% to $37.93 from $17.15 on October 27, 2025, following positive Phase 1b results for TX45 and initiation of multiple clinical trials. UroGen Pharma Ltd. climbed 280% to $38.02 from $10.01 on April 25, 2025, after FDA approval of Zusduri and strong revenue growth. Eton Pharmaceuticals Inc. advanced 128% to $37.50 from $16.44 on December 11, 2025, supported by FDA approval of DESMODA and multiple commercial deals. Liquidia Corp. surged 249% to $78.93 from $22.59 on October 17, 2025, fueled by the launch and expanding adoption of Yutrepia.

The non-muscle invasive bladder cancer market is expected to undergo significant transformation during the 2026 to 2036 forecast period as novel targeted and gene therapies advance through late-stage clinical development. The total market size across the seven major markets, comprising the United States, the EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan, was approximately USD 3 billion in 2025, with the United States holding the largest share. Total prevalent cases of non-muscle invasive bladder cancer in these markets were nearly 1.56 million and are projected to increase by 2036. Key emerging therapies include CG0070 from CG Oncology, EG-70 from enGene, TAR-210 from Janssen, Dabogratinib from Tyra Biosciences, UGN-103 from UroGen Pharma, and TARA-002 from Protara Therapeutics, with cretostimogene grenadenorepvec plus or minus KEYTRUDA expected to generate the highest revenue among all therapies by 2036.